SLC6A6 and pancreatic neoplasm: Cao et al. [80] reported that the taurine transporter SLC6A6 is associated with tumor progression; high SLC6A6 expression was correlated with poor overall survival and progression-free survival in glioblastoma, low-grade glioma, as well as in gastric, liver, and pancreatic cancers.